MPX Bioceutical Corporation (CNSX:MPX) (‘MPX’) signed a letter of intent to acquire 8423695 Canada Inc. for CAD 22.7 million on April 17, 2018. As consideration, MPX will pay CAD 3 million in cash, issue 21.5 million common shares and 6 million common share purchase warrants each exercisable into one MPX share at an exercise price of CAD 0.84 for a period of five years from the date of issuance. The transaction is subject to customary conditions, including signing of definitive documents, completion of satisfactory due diligence, and applicable regulatory (including CSE) approvals, if required. Stoic Advisory Inc. served as financial advisor to MPX and will receive a finder’s fee equal to 1% of the purchase price in MPX shares. MPX Bioceutical Corporation (CNSX:MPX) (‘MPX’) completed the acquisition of 8423695 Canada Inc. for CAD 22.5 million on June 7, 2018. The revised purchase consideration comprised CAD 3.12 million of cash, 21,428,571 common shares in the capital of MPX and 6 million common share purchase warrants each exercisable into one MPX share at an exercise price of CAD 0.84 for a period of five from the date of issuance.